RELAXINDevelopment, Commercialization and License Agreement • March 30th, 1999 • Connetics Corp • Pharmaceutical preparations • New York
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. FIRST AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT between LUPIN LTD. and SALIX PHARMACEUTICALS, INC. Dated as of...Development, Commercialization and License Agreement • May 10th, 2013 • Salix Pharmaceuticals LTD • Pharmaceutical preparations
This FIRST AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Amendment”), dated as of 22 February 2013 (the “First Amendment Effective Date”), is made by and between Lupin Ltd., a corporation organized under the laws of India (“Lupin”), and Salix Pharmaceuticals, Inc., a California corporation (“Salix”). Lupin and Salix are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BY AND AMONG Cti biopharma corp., BAXALTA INCORPORATED BAXALTA US INC. AND BAXALTA GMBHDevelopment, Commercialization and License Agreement • August 6th, 2015 • Cti Biopharma Corp • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Amendment”) is entered into on this 8th day of June, 2015 (the “Effective Date”), by and among CTI BIOPHARMA CORP (f/k/a CELL THERAPEUTICS, INC.), a company organized under the laws of the State of Washington with its principal place of business at 3101 Western Avenue, Seattle, WA 98121 (“CTI”), and BAXALTA INCORPORATED, a company organized under the laws of Delaware with its principal place of business at 1200 Lakeside Drive, Bannockburn, IL 60015 (“BI”), BAXALTA US INC. (“BUSI”) and BAXALTA GMBH (“BGMBH” and, together with BI and BUSI, collectively, “Baxalta”). CTI and Baxalta may each be referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BY AND AMONG CELL THERAPEUTICS, INC., BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA DATED: NOVEMBER 14, 2013Development, Commercialization and License Agreement • March 4th, 2014 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
This DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is entered into on this 14th day of November, 2013 (the “Effective Date”), by and among CELL THERAPEUTICS, INC., a company organized under the laws of the State of Washington with its principal place of business at 3101 Western Avenue, Seattle, WA 98121 (“CTI”), and BAXTER INTERNATIONAL INC., a company organized under the laws of Delaware with its principal place of business at One Baxter Parkway, Deerfield, IL 60015 (“BII”), BAXTER HEALTHCARE CORPORATION, a company organized under the laws of Delaware with its principal place of business at One Baxter Parkway, Deerfield, IL 60015 (“BHC”), and BAXTER HEALTHCARE SA, a company organized under the laws of Switzerland with its principal place of business at Postfach 8010, Zurich, Switzerland (“BHSA” and together with BII and BHC, “Baxter”). CTI and Baxter may each be referred to herein individually as a “Party” and collectively as the “Parties.”
RELAXINDevelopment, Commercialization and License Agreement • May 15th, 2000 • Connetics Corp • Pharmaceutical preparations
